Analysis of the Ten-Eleven Translocation 2 (TET2) gene mutation in myeloproliferative neoplasms.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Annals of Clinical and Laboratory Science

• Publication date

  2014-03-20

• Fields of study

  Medicine

• Identifiers
  PMID 24795056
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms

  2012cited by this paper
• New mutations and pathogenesis of myeloproliferative neoplasms.

  2011cited by this paper
• Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.

  2011cited by this paper
• Tissue Distribution of 5-Hydroxymethylcytosine and Search for Active Demethylation Intermediates

  2010cited by this paper
• Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.

  2010cited by this paper
• Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias

  2010cited by this paper
• Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

  2010cited by this paper
• Chromosomal abnormalities in transformed Ph‐negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations

  2010cited by this paper
• A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications

  2010cited by this paper
• Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.

  2009cited by this paper
• Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.

  2009cited by this paper
• Mutation in TET2 in myeloid cancers.

  2009influential reference
• Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML

  2009cited by this paper
• Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

  2009cited by this paper
• Acquired mutations in TET2 are common in myelodysplastic syndromes

  2009cited by this paper
• The 2008 World Health Organization classification system for myeloproliferative neoplasms

  2009cited by this paper
• TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

  2009cited by this paper
• Dimerization by a Cytokine Receptor Is Necessary for Constitutive Activation of JAK2V617F*

  2008cited by this paper
• MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia

  2006cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

  2005cited by this paper
• A gain-of-function mutation of JAK2 in myeloproliferative disorders.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

  2005cited by this paper
• LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23).

  2002cited by this paper
• Some speculations on the myeloproliferative syndromes.

  1951cited by this paper
• Editorial: Some Speculations on the Myeloproliferative Syndromes

  1951cited by this paper

• Biological Markers of Myeloproliferative Neoplasms in Children, Adolescents and Young Adults

  2024cites this paper
• Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis

  2024cites this paper
• Phenotypic and transcriptomic impact of expressing mammalian TET2 in the Drosophila melanogaster model

  2023cites this paper
• The Prevalence of TET2 Gene Mutations in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms (MPN): A Systematic Review and Meta-Analysis

  2021cites this paper
• Analysis of genetic variants in myeloproliferative neoplasms using a 22-gene next-generation sequencing panel

  2021cites this paper
• JAK2 and TET2 Mutation in Polycythemia Vera

  2021cites this paper
• Frequent Somatic TET2 Mutations in Chronic NK-LGL Leukemia with Distinct Patterns of Cytopenias.

  2021cites this paper
• Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision Oncology

  2021cites this paper
• Coexistence of ten-eleven translocation 2 and calreticulin mutations in myeloproliferative neoplasms: Possible prognostic value

  2020influential citation
• Targeting epigenetic regulators in the treatment of T-cell lymphoma

  2020cites this paper
• miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.

  2020cites this paper
• Epigenetic Regulations in Neural Stem Cells and Neurological Diseases

  2018cites this paper
• Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms

  2018cites this paper
• JAK2V617F allele burden: innovative concept in monitoring of myeloproliferative neoplasms

  2018cites this paper
• Myeloproliferative neoplasms: Current molecular biology and genetics.

  2016cites this paper
• Hydroxymethylation of microRNA-365-3p Regulates Nociceptive Behaviors via Kcnh2

  2016cites this paper
• Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis

  2015cites this paper